Li SH, Chen SQ, Lu T et al. · Life sciences · PMID 42128272
From the original abstract
“MOTS-c attenuates hyperoxic cardiac injury by inhibiting KEAP1-mediated oxeiptosis, highlighting its potential as a novel therapeutic agent for neonatal cardiomyopathy.”
From the abstract’s significance section. This is a short quotation from the authors, not a full study appraisal.
Read the full abstract & conclusionCheck the methods for the exact molecule, preparation, and research model. Measurements of a naturally occurring peptide differ from testing its administration. Cell and animal findings need separate evaluation in people.
A brief excerpt cannot capture the complete methods, results, adverse events, or limitations. Check the full abstract and original paper before interpreting the finding.
Educational research information. A publication does not verify the identity, quality, or safety of products sold here.
Back to MOTS-c studies